Back to top
more

Agenus (AGEN)

(Delayed Data from NSDQ)

$5.36 USD

5.36
267,519

-0.16 (-2.90%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $5.34 -0.02 (-0.37%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Kura Oncology (KURA) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Kura Oncology (KURA) delivered earnings and revenue surprises of 65.08% and 76.49%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Kiniksa Pharmaceuticals (KNSA) delivered earnings and revenue surprises of -100% and 0.71%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Agenus (AGEN) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.

Zacks Equity Research

Travere Therapeutics (TVTX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Travere (TVTX) delivered earnings and revenue surprises of -25.86% and 1.84%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Agenus (AGEN) Is Attractively Priced Despite Fast-paced Momentum

by Zacks Equity Research

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Agenus (AGEN) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks Equity Research

Are Medical Stocks Lagging Agenus (AGEN) This Year?

by Zacks Equity Research

Here is how Agenus (AGEN) and Concentra Group (CON) have performed compared to their sector so far this year.

Zacks Equity Research

What Makes Agenus (AGEN) a New Buy Stock

by Zacks Equity Research

Agenus (AGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Agenus (AGEN) and Abbott (ABT) have performed compared to their sector so far this year.

Zacks Equity Research

Agenus (AGEN) Loses -41.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

Agenus (AGEN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks Equity Research

Agenus (AGEN) Loses -41.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

The heavy selling pressure might have exhausted for Agenus (AGEN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks Equity Research

Down -39.39% in 4 Weeks, Here's Why Agenus (AGEN) Looks Ripe for a Turnaround

by Zacks Equity Research

Agenus (AGEN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks Equity Research

Agenus (AGEN) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Agenus (AGEN) delivered earnings and revenue surprises of -50.95% and 35.82%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Aveanna Healthcare (AVAH) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Aveanna (AVAH) delivered earnings and revenue surprises of 300% and 2.67%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Agenus (AGEN) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Agenus (AGEN) delivered earnings and revenue surprises of -89.47% and 63.68%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AC Immune (ACIU) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

AC Immune (ACIU) delivered earnings and revenue surprises of -159.52% and 99.17%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Agenus (AGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

by Zacks Equity Research

Agenus (AGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

What Awaits Biogen (BIIB) in Q2 Earnings Post Leqembi Setback?

by Zacks Equity Research

Biogen's (BIIB) sales in the second quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have been hurt by increased competition.

Zacks Equity Research

The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen Agenus and BioMarin Pharmaceutical

by Zacks Equity Research

Sage Therapeutics, Biogen Agenus and BioMarin Pharmaceutical are part of the Zacks top Analyst Blog.

Ekta Bagri headshot

Biotech Stock Roundup: SAGE Plunges on Study Failure, AGEN Down on Regulatory Update & More

by Ekta Bagri

Sage Therapeutics (SAGE) and Agenus (AGEN) are in the spotlight following study failure and regulatory updates, respectively.

Zacks Equity Research

What's in Store for Structure Therapeutics (GPCR) in Q2 Earnings?

by Zacks Equity Research

Structure Therapeutics (GPCR) is expected to provide updates on the developmental pathway of its lead product candidate, GSBR-1290, for diabetes and obesity indications in the Q2 earnings release.

Zacks Equity Research

Geron (GERN) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Geron (GERN) is expected to primarily provide updates regarding the launch of its newly approved hematologic malignancy drug, Rytelo, in the United States when it reports second-quarter earnings.

Zacks Equity Research

Agenus (AGEN) Tanks on Colorectal Cancer Study Interim Data

by Zacks Equity Research

The FDA rejects the accelerated approval pathway for Agenus' (AGEN) BOT/BAL combination in relapsed/refractory microsatellite stable colorectal cancer patients.

Zacks Equity Research

IGM Biosciences (IGMS) Soars 32.7%: Is Further Upside Left in the Stock?

by Zacks Equity Research

IGM Biosciences (IGMS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Ligand (LGND) Beats Q1 Earnings, Misses Sales Estimates

by Zacks Equity Research

Ligand Pharmaceuticals (LGND) reports mixed first-quarter results. Management reiterates the 2024 financial outlook.

Zacks Equity Research

Agenus (AGEN) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Agenus (AGEN) delivered earnings and revenue surprises of 15.08% and 31.19%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?